DP
SPRB

Diadema Partners’s Spruce Biosciences SPRB Stock Holding History

Diadema Partners’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
30,000
+20,000
+200% +$1.12M 0.2% 86
2026
Q1 		$654K Buy
+10,000
New +$690K 0.11% 101

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

Diadema Partners's SPRB Position: Q2 2026 in Review

Diadema Partners increased its Spruce Biosciences (SPRB) stake by 200% in Q2 2026, buying an estimated $1.12M and bringing the position to 30,000 shares worth $1.62M. The position accounts for 0.2% of the portfolio, ranked #86.

Diadema Partners first reported a position in SPRB in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Diadema Partners held 30,000 shares of Spruce Biosciences worth $1.62M as of Q2 2026.
  • Diadema Partners bought 20,000 Spruce Biosciences shares in Q2 2026, an estimated $1.12M.
  • Spruce Biosciences made up 0.2% of Diadema Partners's portfolio in Q2 2026, its #86 holding.
  • Diadema Partners first reported a position in Spruce Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.